NEW YORK, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of all persons or entities who purchased or otherwise acquired Jasper Therapeutics, Inc. (“Jasper” or the “Company”) (NASDAQ: JSPR) securities between November 30, 2023 and July 3, 2025, inclusive (the “Class Period”). The Complaint alleges that Defendants made false and/or misleading state ...

Alector (NasdaqGS:ALEC) Update / Briefing September 22, 2025 12:00 PM ET Company ParticipantsKatie Hogan - Senior Director - Corporate Communication & IRSara Kenkare-Mitra - President & Head - Research & DevelopmentArnon Rosenthal - Co-Founder, CEO & DirectorPete Stavropoulos - Director - Biotech Equity ResearchGiacomo Salvadore - Chief Medical OfficerJulian Pino - Senior Associate - Biotechnology Equity ResearchAlec Stranahan - VP - Equity ResearchGraig Suvannavejh - Managing DirectorConference Call Partic ...

ATLANTA, Sept. 22, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Jasper Therapeutics, Inc. (“Jasper” or the “Company”) (NASDAQ: JSPR). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information regarding Jasper’s business, operations, and compliance policies, including allegations that: (i) Jasper lacked the controls and procedures necessary to ensure that the third-party manufacturers on ...

Pfizer has acquired Metsera for $4.9bn, as the drugmaker targets longer-lasting glucagon-like peptide-1 receptor agonists (GLP-1RAs) to cement market share in the burgeoning weight loss treatment sector. Pfizer has agreed to buy all of Metsera’s shares for a price of $47.50 each, representing a 43% premium to Metsera’s closing share price of $33.32 on 19 September. The deal, forecast to close in Q4 2025, also includes potential additional payments of up to $22.50 per share in cash tied to three specific c ...

U.S. stocks traded mostly higher midway through trading, with the Nasdaq Composite gaining over 50 points on Monday.The Dow traded up 0.01% to 46,321.12 while the NASDAQ rose 0.24% to 22,685.77. The S&P 500 also rose, gaining, 0.15% to 6,674.60.Check This Out: Top 2 Tech Stocks That May Plunge This MonthLeading and Lagging SectorsInformation technology shares jumped by 0.4% on Monday.In trading on Monday, consumer staples stocks fell by 0.5%.Top HeadlinePfizer Inc. PFE on Monday agreed to acquire Metsera, I ...

NEW YORK , Sept. 22, 2025 /PRNewswire/ -- Attorney Advertising --Â Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cytokinetics, Incorporated ("Cytokinetics" or "the Company") (NASDAQ: CYTK) and certain of its officers. ...

现金流与财务状况 - Alector拥有超过3亿美元的现金，预计可支持运营至2027年下半年[13] 临床试验与研发进展 - FTD-GRN的关键临床试验数据预计在2025年第四季度中期发布[13] - 阿尔茨海默病的Phase 2临床试验于2025年4月完成入组[13] - Alector Brain Carrier的首次人体临床试验预计在2026年进行[13] - Latozinemab和Nivisnebart在临床试验中显示出PGRN水平增加2到3倍，且总体耐受性良好[50] - INFRONT-2试验中，Latozinemab治疗的FTD-GRN患者PGRN水平恢复至健康对照组的水平[54] - Latozinemab治疗后，FTD-GRN患者的GFAP水平下降，接近无症状FTD-GRN携带者的基线水平[57] - Latozinemab的临床结果显示，年进展速度减少约48%（3.1分变化）[61] - Nivisnebart的Phase 2 PROGRESS-AD研究已于2025年4月完成入组[68] - Nivisnebart的主要终点是CDR-SB在52、64和76周的基线变化[70] - Latozinemab的关键数据预计在2025年第四季度中期发布[65] - Nivisnebart的治疗期为76周，并将在2026年上半年进行独立的中期分析[69] 市场潜力与用户数据 - FTD-GRN在美国和欧盟的患者人数估计为8000至17000人，占FTD的5%至10%[24] - FTD的疾病负担估计是阿尔茨海默病的近两倍[24] - 约30%的FTD-GRN患者被误诊为未特定类型的痴呆[27] 产品与技术创新 - AL037在小鼠大脑中显示出Aβ42水平的显著降低，50 mg/kg剂量下p=0.035[104] - AL037在非人灵长类动物(NHP)中的血清半衰期为106小时，而AL037-Naked为192小时[108] - AL037在NHP的前额叶皮层中达到3.8 nM，较其他脑载体高出约5倍[114] - AL137在NHP的前额叶皮层中达到8.4 nM，较其他脑载体高出约12倍[117] - AL050在NHP血浆中的半衰期比当前的GCase酶替代疗法长约10倍[141] - AL050在NHP血浆中显示出约40倍于当前GCase酶替代疗法(ERT)的酶活性[143] - AL050在NHP大脑中增加GCase活性超过2倍，具体为海马区132%、黑质112%、纹状体63%和额叶124%的增加[153] - AL050在Gba1突变小鼠的肝脏中GlcSph水平减少87%，并且GCase活性在注射24小时后得到恢复[158] - AL050在Gba1突变小鼠的大脑中实现了GlcSph的持久减少，减少幅度约为80%[161] - Alector Brain Carrier (ABC)增强了工程化GCase载体在大脑中的递送，提升幅度为5到19倍[149] 合作与财务协议 - Alector与合作伙伴的协议包括7亿美元的预付款和15亿美元的潜在里程碑付款[73] 未来展望 - Alector正在专注于推动临床项目的进展，预计在2026至2027年间有明确的价值创造催化剂[185] - 预计2027年进行首次人体试验，针对与GBA1基因突变相关的高达100万例帕金森病病例和240万例路易体痴呆病例[167]

SAN FRANCISCO, Sept. 22, 2025 (GLOBE NEWSWIRE) -- On September 15, 2025, investors in aTyr Pharma, Inc. (NASDAQ: ATYR) saw the price of their shares crater over 80% after the company reported that its late-stage study of efzofitimod for treating pulmonary sarcoidosis, a significant type of interstitial lung disease (“ILD”), did not meet its main goal. The development and severe market reaction has prompted national shareholders rights firm Hagens Berman to open an investigation into whether aTyr may have mi ...

U.S. stocks traded mostly lower this morning, with the Dow Jones index falling more than 100 points on Monday.Following the market opening Monday, the Dow traded down 0.25% to 46,201.74 while the NASDAQ rose 0.05% to 22,642.88. The S&P 500 also fell, dropping, 0.07% to 6,659.98.Check This Out: Top 2 Tech Stocks That May Plunge This MonthLeading and Lagging SectorsConsumer discretionary shares jumped by 0.2% on Monday.In trading on Monday, energy stocks fell by 0.6%.Top HeadlineThe Chicago Fed National Activ ...

ANALYSIS: Weight-Loss Craze Boosts This $186 Billion IndustryTempus AI (TEM) stock surged to a record-high Monday after the Food and Drug Administration cleared its new device to help drugmakers analyze RNA.RNA analysis is helpful in determining the mechanisms of diseases and finding molecular pathways to target specific conditions."We have long known that RNA sequencing offers additional insights beyond DNA alone, but only now are we beginning to unlock is full value in supporting therapeutic development," ...